All News

Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.

“We see that those taking chemotherapy are going to be the ones that are going to require the most help,” Clara Bodelon, PhD, MS, said regarding breast cancer treatment.

“[There] is a need to make sure that everybody is coming in and bringing their expertise together,” Valerie Lee, MD, said.

Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.

For Terri Lynn Shigle, PharmD, the field of hematology-oncology is deeply personal. Having lost loved ones to cancer, she was drawn to a career where she could make a meaningful difference in patient care.

In celebration of Women’s History Month, ASTCT is proud to highlight the inspiring journeys of women making a profound impact in transplantation and cellular therapy.

Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

At 5 years, 100% of patients with breast cancer who did not receive surgery had ipsilateral breast tumor relapse-free survival.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

Tisotumab vedotin elicited a median OS of 11.5 months vs 9.5 months with chemotherapy in advanced cervical cancer in the phase 3 innovaTV 301 trial.

Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.

Patients with breast cancer who were treated with chemotherapy may have more pain, fatigue, and difficulty moving vs those who received endocrine therapy or did not have breast cancer.

Valerie Lee, MD, said that deciding where to implement immunotherapy into cancer treatment often depends on the type of disease.

A radiation oncologist discussed challenges related to the radiation oncology space as well as ongoing developments in the field highlighted at ACRO.

A stronger commitment to tobacco control at the local, state, and federal levels may further improve progress in preventing smoking-related mortality.

CAN-2409 plus valacyclovir or acyclovir elicited a median OS of 24.5 months in the overall population of patients who progressed after immune checkpoint inhibitor therapy.

Intravenous olvi-vec demonstrated a manageable safety and tolerability profile consistent with previous trials evaluating the investigational agent.

A radiation oncologist discussed the theranostics treatment landscape and career opportunities in the field at the 2025 ACRO Summit.

Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk.

The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.

A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.

ACRO presentations may enable community practices to utilize cutting-edge radiation advances to deliver optimal treatment to patients.

In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.

Antibody-drug conjugates like Rina-S may be able to salvage some of the responses that are often lost in the later lines of treatment, according to Elizabeth Lee, MD.

Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.

Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.